Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(100.0%)
1Total
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03545126Completed

Human CNS Tau Kinetics in Tauopathies

Role: collaborator

NCT02365922Completed

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

Role: collaborator

NCT02133846Phase 1Completed

Safety Study of TPI-287 to Treat CBS and PSP

Role: collaborator

All 3 trials loaded